{
  "id": 1467098,
  "title": "AstraZeneca cans late-stage volrustomig trial after lung cancer setback",
  "url": "https://urgent.news/2026/08/17/astrazeneca-cans-late-stage-volrustomig-trial-after-lung-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-17T10:47:39.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/astrazeneca-cans-late-stage-volrustomig-trial-after-lung-cancer-setback/"
  },
  "original_language": "en",
  "account": null,
  "summary": "AstraZeneca has discontinued a Phase 3 study of one of its cancer drugs. According to Endpoints News, this is the latest in a series of setbacks for the drugmaker.\n\nThe study in question was the SAFFRON Phase III trial, which was investigating the combination of Tagrisso (osimertinib) and Orpathys (savolitinib) for patients with EGFR-mutated non-small cell lung cancer.\n\nInvesting.com reports that the trial showed statistically significant improvements in progression-free survival and overall survival compared to platinum-based chemotherapy. However, despite these results, AstraZeneca decided to end the study.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "AstraZeneca’s Tagrisso plus Orpathys extends survival in lung cancer",
        "url": "https://urgent.news/2026/08/17/astrazenecas-tagrisso-plus-orpathys-extends-survival-in-lung-cancer",
        "published": "2026-08-17T06:25:05.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}